Authors
Dean Sabayon, Deaa Abu Jazar, Khaled Alabdallah, Ritika Saxena, Ivana Garza, Arun Narayanan, Haidar Al Taii, Dustin Staloch, Hani Jneid
Published in
The Journal of innovations in cardiac rhythm management. Volume 17. Issue 9. Pages 6850-6853. Epub Sep 15, 2026.
Abstract
Pulsed field ablation (PFA) using the Farapulse™ system (Boston Scientific, Marlborough, MA, USA) is a novel, non-thermal ablation technology developed to treat atrial fibrillation (AF) with improved safety and procedural efficiency. We present prospective single-center data on the safety, efficacy, and effectiveness of PFA in a real-world patient population. We enrolled 100 consecutive patients with symptomatic AF undergoing catheter ablation with the Farapulse™ system. Procedural characteristics, clinical outcomes, and acute safety events were evaluated. Freedom from AF recurrence was assessed at 6 months. The cohort had a mean age of 69.2 ± 10.9 years, and 47% were women. Pulmonary vein isolation was achieved in 96% of patients, with additional posterior wall ablation performed in 66%. The median procedure and fluoroscopy times were 42 and 12 min, respectively. No major adverse events occurred. At 6 months, 82% of patients were free from atrial arrhythmia recurrence off anti-arrhythmic drugs. PFA with the Farapulse™ system demonstrated high acute efficacy, excellent safety, and promising short-term effectiveness in a real-world population with AF. These findings support the broader adoption of PFA in routine clinical practice.
PMID:
42877885
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0